RankingsPricing
  1. US-listed companies
  2. OCULAR THERAPEUTIX, INC
  3. Financials
  4. EBITDA

OCULAR THERAPEUTIX, INCOCUL

Market cap
$2.3B
P/E ratio
SummaryFinancials
Period EndEBITDA (Million USD)YoY (%)
Dec 31, 2024-168+111.58%
Dec 31, 2023-79+3.73%
Dec 31, 2022-77+1.23%
Dec 31, 2021-76+25.87%
Dec 31, 2020-60-27.86%
Dec 31, 2019-83+46.52%
Dec 31, 2018-57-5.75%
Dec 31, 2017-60+42.06%
Dec 31, 2016-42+13.36%
Dec 31, 2015-37+41.04%
Dec 31, 2014-27

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)